MedTrace Logo

Carboplatin Plus Gemcitabine for Elderly Patients With Stage IV NSCLC

NCT02175381 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2015-05-15

No results posted yet for this study

Summary

The investigators propose to study the safety and efficacy of the combination of Carboplatin plus Gemcitabine in a Phase I/II trial of elderly subjects with non-small cell lung cancer.

Conditions

Interventions

DRUG

Carboplatin

Carboplatin: 2.5 AUC i.v on day 1. Cycle repeated ever 2 weeks

DRUG

Gemcitabine

Gemcitabine: 1100 mg/m2, iv on day 1. Cycle repeated every 2 weeks

Sponsors & Collaborators

  • Hellenic Oncology Research Group

    lead OTHER

Principal Investigators

  • Lambros Vamvakas, MD · University Hospital of Herklion

  • Athanasios Karambeazis, MD · Medical Oncology Unit NIMTS (Veterans Hospital)

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02175381 on ClinicalTrials.gov